Wall Street analysts expect Glaukos Co. (NYSE:GKOS – Get Rating) to post earnings of ($0.44) per share for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for Glaukos’ earnings. The lowest EPS estimate is ($0.50) and the highest is ($0.35). Glaukos posted earnings of ($0.11) per share during the same quarter last year, which suggests a negative year over year growth rate of 300%. The firm is scheduled to announce its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Glaukos will report full-year earnings of ($1.94) per share for the current fiscal year, with EPS estimates ranging from ($2.74) to ($1.70). For the next fiscal year, analysts expect that the company will post earnings of ($1.56) per share, with EPS estimates ranging from ($2.10) to ($1.19). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Glaukos.
Glaukos (NYSE:GKOS – Get Rating) last issued its earnings results on Wednesday, May 4th. The medical instruments supplier reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.13. The firm had revenue of $67.70 million during the quarter, compared to analysts’ expectations of $60.85 million. Glaukos had a negative net margin of 9.45% and a negative return on equity of 7.95%. The firm’s revenue was down .4% compared to the same quarter last year. During the same quarter last year, the company posted ($0.21) earnings per share.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp raised its stake in Glaukos by 1.3% during the third quarter. Bank of New York Mellon Corp now owns 465,592 shares of the medical instruments supplier’s stock worth $22,427,000 after purchasing an additional 6,104 shares during the period. AlphaCrest Capital Management LLC raised its stake in Glaukos by 130.0% during the fourth quarter. AlphaCrest Capital Management LLC now owns 30,901 shares of the medical instruments supplier’s stock worth $1,373,000 after purchasing an additional 17,468 shares during the period. Panagora Asset Management Inc. purchased a new position in Glaukos during the fourth quarter worth about $935,000. Primecap Management Co. CA raised its stake in Glaukos by 12.5% during the third quarter. Primecap Management Co. CA now owns 500,200 shares of the medical instruments supplier’s stock worth $24,095,000 after purchasing an additional 55,700 shares during the period. Finally, Yousif Capital Management LLC purchased a new position in Glaukos during the fourth quarter worth about $1,866,000. Hedge funds and other institutional investors own 92.52% of the company’s stock.
GKOS stock traded up $0.31 during midday trading on Friday, hitting $39.34. 380,678 shares of the stock traded hands, compared to its average volume of 721,383. The firm has a market cap of $1.86 billion, a P/E ratio of -64.49 and a beta of 1.52. The company has a debt-to-equity ratio of 0.59, a current ratio of 8.84 and a quick ratio of 8.39. The stock’s fifty day simple moving average is $52.18 and its 200-day simple moving average is $50.46. Glaukos has a 1-year low of $33.33 and a 1-year high of $87.24.
About Glaukos (Get Rating)
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
- Get a free copy of the StockNews.com research report on Glaukos (GKOS)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.